Dexorgen

Executive Summary

Dexorgen is an advanced biotechnology company specializing in high-throughput, live-cell assay solutions for drug discovery and toxicity testing, with a particular focus on G-protein coupled receptors (GPCRs) and phosphodiesterases (PDEs). Headquartered in Maryland with operations in San Diego, the company leverages its proprietary live-cell technology and AI-driven analytics to enable efficient and accurate compound screening. By addressing critical bottlenecks in preclinical research, Dexorgen aims to reduce the time and cost of bringing new therapeutics to market. Despite its relatively early stage and limited public data, the company's targeted approach in a high-demand area of drug development positions it as a potential partner for pharmaceutical firms seeking to accelerate their pipelines. Its inclusion in the biopharmguy database and status as an approved entity suggest it has passed initial diligence hurdles, though details on funding and customer traction remain sparse.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation GPCR Assay Platform70% success
• H1 2027Strategic Partnership with Major Pharma for PDE Screening50% success
• Q2 2027Series A Funding Announcement60% success